Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Pisa, Italy
Countries of investment
  • Italy
  • Germany
  • Switzerland
  • United Kingdom
  • Ireland
  • Spain
  • Greece
  • Portugal
  • Mexico
  • China
  • Taiwan
  • Saudi Arabia
  • Iraq
  • Israel
  • United Arab Emirates
  • Canada
Investment stages
  • Series B
  • Series C
  • Growth
Industries
  • Pharmaceuticals
  • Biotechnology
  • Life Sciences
About
Abiogen Pharma drives pharmaceutical innovation as a leading Italian player specializing in endocrinology, pain management, rare diseases, bone health, and orphan conditions, expanding globally through strategic acquisitions, robust R&D pipelines, and partnerships across Europe, Asia, and the Americas for patient-centric advancement.
Min check size
$8.5M
Max check size
$8.5M
Fund size
NPS

Investment Thesis

Abiogen Pharma advances pharmaceutical innovation in endocrinology, pain management, rare diseases, and musculoskeletal health through R&D excellence, global partnerships, and patient-focused product development.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Led by pharmaceutical and biotech executives with deep experience in drug development, clinical research, and commercialization within regulated markets.

Abiogen Pharma Contacts Information

Primary contact

Secondary contact

Team

Massimo Di Martino - Chairman and President

Paolo Zambonardi - Chief Executive Officer

Portfolio

EffRx

Altamedics

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp